会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS
    • 主席UNDITEXIMALE LEBERSTAMMZELLEN
    • EP1490480B1
    • 2016-02-03
    • EP03728245.6
    • 2003-03-14
    • University of North Carolina at Chapel HillIncara Cell Technologies, Inc.
    • REID, LolaMOSS, Nicholas, G.FURTH, Mark, E.LUDLOW, John, W.BRUCE, Andrew, T.
    • C12N5/071C12N5/074A61K35/413
    • C12N5/0672C12N2500/25C12N2500/36C12N2500/90C12N2501/11C12N2502/13G01N33/5005G01N33/68G01N2333/705G01N2333/70525G01N2333/70596
    • Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.
    • 肝祖细胞包含两个人类肝干细胞,原始和近端肝干细胞,以及两个定型祖细胞群,一个为胆汁细胞,一个为肝细胞。 人原始肝干细胞是肝细胞群体的一小部分,并且产生近肝组织肝脏部分的肝干细胞。 人近端肝干细胞产生胆汁和肝细胞定向的祖细胞。 原始和近端干细胞是人类肝脏的主要干细胞。 人原始肝干细胞可以通过人肝脏的免疫选择或在选择人原始肝干细胞的条件下培养人肝细胞来分离。 可以通过免疫选择或通过在包括发育因子的条件下培养人肝细胞来分离近端肝干细胞。 也可以通过在包括发育因子的条件下培养包含原始肝干细胞的菌落来分离近端肝干细胞。 所得组合物可用于治疗肝脏疾病和用于生产生物人造器官。
    • 6. 发明公开
    • Crude drug extract containing soluble silicon
    • Ein Roharzneimittel Extrakt enthaltendelöslissSilizium
    • EP0919238A3
    • 1999-10-27
    • EP98122198.9
    • 1998-11-27
    • NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    • Konishi, Jin-emon
    • A61K35/12A61K35/413A61K35/78A61K35/84G01N33/52
    • G01N33/52A61K36/00A61K36/07A61K2300/00
    • [Object of the Invention] The present invention is to offer a crude drug extract containing soluble silicon compounds as an effective component and also to offer a standardization method therefor. [Means for Achieving That] The crude drug extract of the present invention can be prepared by extraction of various crude drugs derived from animals, plants, etc. and quality of the crude drug extract can be standardized using the soluble silicon compounds as an index. [Merit] As such, in accordance with the present invention, soluble silicon compounds related to the pharmaceutical effect is used as an index whereby quality of various crude drugs can be standardized which contributes to offer crude drug extracts having a stable quality. Consequently, the present invention greatly contributes to the appropriate standardization of pharmaceuticals.
    • 本发明提供含有可溶性硅化合物的生物药物提取物作为有效成分,并提供其标准化方法。 Ä实现方法本发明的生药提取物可以通过提取源自动物,植物等的各种生药来制备,并且可以使用可溶性硅化合物作为指标来标准化生物药物提取物的质量。 ÄMeritÜ因此,根据本发明,使用与药效有关的可溶性硅化合物作为指标,其中可以标准化各种生药的质量,这有助于提供具有稳定质量的生药提取物。 因此,本发明大大有助于药物的适当标准化。